Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
about
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Effect of trabectedin on the QT interval in patients with advanced solid tumor malignanciesPharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.
P2860
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
@en
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
@nl
type
label
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
@en
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
@nl
prefLabel
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
@en
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
@nl
P2093
P1476
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743)
@en
P2093
Jan H M Schellens
Jos H Beijnen
Olaf van Tellingen
P356
10.2174/157488409787236047
P577
2009-01-01T00:00:00Z